Corrigendum: Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.

Autor:	Sivera F; Rheumatology Department, Hospital General Universitario de Elda, Alicante, Spain.; Departament of Clinical Medicine, Universidad Miguel Hernandez, Elche, Spain., Núñez-Monje V; Rheumatology Department, Hospital Universitario Dr Peset, Valencia, Spain., Campos-Fernández C; Rheumatology Department, Hospital General Universitario, Valencia, Spain., Balaguer-Trull I; Rheumatology Department, Hospital General Universitario, Valencia, Spain., Robustillo-Villarino M; Reumatology Unit, Internal Medicine Department, Hospital Universitario de la Plana, Villarreal, Spain., Aguilar-Zamora M; Rheumatology Department, Hospital de Sagunto, Sagunto, Spain., Garijo-Bufort M; Rheumatology Department, Hospital de Sagunto, Sagunto, Spain., López-Gómez JM; Rheumatology Department, Hospital General Universitario de Elda, Alicante, Spain., Peña-González C; Rheumatology Department, Hospital Francesc de Borja, Gandía, Spain., de la Morena I; Rheumatology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Bedoya-Sanchís D; Rheumatology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Yankova-Komsalova L; Rheumatology Department, Hospital Marina Salud, Denia, Alicante, Spain., Conesa-Mateos A; Rheumatology Department, Hospital General Universitari de Castelló, Castellón, Spain., Martínez-Cristóbal A; Rheumatology Department, Hospital Universitario de La Ribera, Alzira, Spain., Navarro-Blasco FJ; Rheumatology Department, Hospital Universitario de Elche, Elche, Alicante, Spain., Senabre-Gallego JM; Rheumatology Department, Hospital Marina Baixa, La Vila Joiosa, Spain., Alegre-Sancho JJ; Rheumatology Department, Hospital Universitario Dr Peset, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2024 Sep 10; Vol. 11, pp. 1462054. Date of Electronic Publication: 2024 Sep 10 (Print Publication: 2024).
DOI:	10.3389/fmed.2024.1462054
Abstrakt:	[This corrects the article DOI: 10.3389/fmed.2023.1156557.]. Competing Interests: “FS received honoraria as a consultant from AbbVie, Pfizer, and AstraZeneca. Grant/Research support from AbbVie, Novartis, Eli Lilly, Roche, and BMS. JS-G reports personal fees and non-financial support from Abbvie, non-financial support from BMS, personal fees from Celgene, personal fees from Janssen, non-financial support from Lilly, non-financial support from MSD, personal fees from Novartis, non-financial support from Pfizer, non-financial support from Roche, non-financial support from UCB, outside the submitted work. This study received funding from Novartis Farmacéutica, S.A. The funder had the following involvement in the study: study design, interpretation of data, the writing of this article, and the decision to submit it for publication. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. (Copyright © 2024 Sivera, Núñez-Monje, Campos-Fernández, Balaguer-Trull, Robustillo-Villarino, Aguilar-Zamora, Garijo-Bufort, López-Gómez, Peña-González, de la Morena, Bedoya-Sanchís, Yankova-Komsalova, Conesa-Mateos, Martínez-Cristóbal, Navarro-Blasco, Senabre-Gallego and Alegre-Sancho.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu